Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 1025, pseudogene (RNU6-1025P) is a noncoding RNA locus classified as a pseudogene in the genome, related by sequence to the highly conserved U6 small nuclear RNA (snRNA) but lacking protein-coding and canonical snRNA function. RNU6-1025P is a genomic pseudogene derived from the highly conserved U6 small nuclear RNA gene locus. U6 snRNA is an essential noncoding RNA involved in the spliceosome complex, mediating pre-mRNA splicing in eukaryotic nuclei. RNU6-1025P, however, is a pseudogene — it retains sequence similarity to U6 but has lost the capacity for normal snRNA function due to disabling mutations or truncations. Pseudogenes, including RNU6-1025P, are generally considered functionless copies or remnants of active genes, although in rare cases they may influence biological processes through regulatory RNA functions; no such role has been established for RNU6-1025P. This locus is not a drug target, does not encode a functional protein or RNA component, and is not associated with any known disease state or therapeutic intervention. It is important not to confuse RNU6-1025P with functionally active U6 snRNA, which is a central RNA component of the spliceosome complex. RNU6-1025P is a “processed pseudogene”—likely arising via retrotransposition—and annotated as such in genomic databases. There is no evidence that RNU6-1025P is transcribed, functions as an lncRNA, or acts as a biomarker or therapeutic target. In summary, RNU6-1025P is an inactive, non-protein-coding RNA pseudogene, related by sequence to U6 snRNA but not involved in splicing or disease biology, and is not considered a molecular target for drug discovery or therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 1025, pseudogene (RNU6-1025P).